Fermilab: Muon g-2 announces most precise measurement of the magnetic anomaly of the muon
Muon g-2 ring
Results plot graph
Batavia, Ill., June 04, 2025 (GLOBE NEWSWIRE) -- Scientists working on the Muon g-2 experiment, hosted by the U.S. Department of Energy's Fermi National Accelerator Laboratory, have released their third and final measurement of the muon magnetic anomaly. This value is related to g-2, the experiment's namesake measurement. The final result agrees with their published results from 2021 and 2023 but with a much better precision of 127 parts-per-billion, surpassing the original experimental design goal of 140 parts-per-billion.
'The anomalous magnetic moment, or g–2, of the muon is important because it provides a sensitive test of the Standard Model of particle physics. This is an exciting result and it is great to see an experiment come to a definitive end with a precision measurement,' said Regina Rameika, the U.S. Department of Energy's Associate Director for the Office of High Energy Physics.
This long-awaited result is a tremendous achievement of precision and will remain the world's most precise measurement of the muon magnetic anomaly for many years to come. Despite recent challenges with the theoretical predictions that reduce evidence of new physics from muon g-2, this result provides a stringent benchmark for proposed extensions of the Standard Model of particle physics.
'This is a very exciting moment because we not only achieved our goals but exceeded them, which is not very easy for these precision measurements,' said Peter Winter, a physicist at Argonne National Laboratory and co-spokesperson for the Muon g-2 collaboration. 'With the support of the funding agencies and the host lab, Fermilab, it has been very successful overall, as we reached or surpassed pretty much all the items that we were aiming for.'
'For over a century, g-2 has been teaching us a lot about the nature of nature,' said Lawrence Gibbons, professor at Cornell University and analysis co-coordinator for this result. 'It's exciting to add a precise measurement that I think will stand for a long time.'
The Muon g-2 (pronounced 'gee minus two') experiment looks at the wobble of a fundamental particle called the muon. Muons are similar to electrons but about 200 times more massive; like electrons, muons have a quantum mechanical property called spin that can be interpreted as a tiny internal magnet. In the presence of an external magnetic field, the internal magnet will wobble — or precess — like the axis of a spinning top.
The precession speed in a magnetic field depends on properties of the muon described by a number called the g-factor. Theoretical physicists calculate the g-factor based on the current knowledge of how the universe works at a fundamental level, which is contained in the Standard Model of particle physics.
Nearly 100 years ago, the value of g was predicted to be 2. But experimental measurements soon showed g to be slightly different from 2 by a quantity known as the magnetic anomaly of the muon, aμ, calculated with (g-2)/2. The Muon g-2 experiment gets its name from this relation.
The muon magnetic anomaly encodes the effects of all Standard Model particles, and theoretical physicists can calculate these contributions to an incredible precision. But previous measurements taken at Brookhaven National Laboratory in the late 1990s and early 2000s showed a possible discrepancy with the theoretical calculation at that time.
When experiment doesn't align with theory, it could indicate new physics. Specifically, physicists wondered if this discrepancy could be caused by as-yet undiscovered particles pulling at the muon's precession.
So physicists decided to upgrade the Muon g-2 experiment to make a more precise measurement. In 2013, Brookhaven's magnetic storage ring was transported from Long Island, New York, to Fermilab in Batavia, Illinois. After years of significant upgrades and improvements, the Fermilab Muon g-2 experiment started up on May 31, 2017.
In parallel, an international collaboration of theorists formed the Muon g-2 Theory Initiative to improve the theoretical calculation. In 2020, the Theory Initiative published an updated, more precise Standard Model value based on a technique that uses input data from other experiments.
The discrepancy with the result from that technique continued to grow in 2021 when Fermilab announced its first experimental result, confirming the Brookhaven result with a slightly improved precision. At the same time, a new theoretical prediction came out based on a second technique that heavily relies on computational power. This new number was closer to the experimental measurement, narrowing the discrepancy.
Recently, the Theory Initiative published a new prediction combining the results of several groups that used the new computational technique. This result remains closer to the experimental measurement, dampening the possibility of new physics. However, the theoretical effort will continue to work to understand the discrepancy between the data-driven and computational approaches.
The latest experimental value of the magnetic moment of the muon from the Fermilab experiment is:
aμ = (g-2)/2 (muon, experiment) = 0.001 165 920 705 +- 0.000 000 000 114(stat.) +- 0.000 000 000 091(syst.)
This final measurement is based on the analysis of the last three years of data, taken between 2021 and 2023, combined with the previously published datasets. This more than tripled the size of the dataset used for their second result in 2023, and it enabled the collaboration to finally achieve their precision goal proposed in 2012.
It also represents an analysis of the experiment's best-quality data. Toward the end of their second data-taking run, the Muon g-2 collaboration finished tweaks and enhancements to the experiment that improved the quality of the muon beam and reduced uncertainties.
The Muon g-2 collaboration describes the result in a paper that they submitted today to Physical Review Letters.
'As it has been for decades, the magnetic moment of the muon continues to be a stringent benchmark of the Standard Model,' said Simon Corrodi, assistant physicist at Argonne National Laboratory and analysis co-coordinator. 'The new experimental result sheds new light on this fundamental theory and will set the benchmark for any new theoretical calculation to come.'
A future experiment at the Japan Proton Accelerator Research Complex will likely make another measurement of the muon magnetic anomaly in the early 2030s, but, initially, they won't achieve the same precision as Fermilab.
Meanwhile, the Theory Initiative will continue working to resolve the inconsistency between their two theoretical predictions.
The Muon g-2 collaboration is made up of nearly 176 scientists from 34 institutions in seven countries. Marco Incagli, a physicist with the Italian National Institute for Nuclear Physics at Pisa and co-spokesperson for Muon g-2, emphasized that the internationality of the collaboration was key to the success of the experiment.
Unusually, the scientists also represent a variety of physics areas. 'This experiment is quite peculiar because it has very different ingredients in it,' said Incagli. 'It is really done by a collaboration among communities that normally work on different experiments.'
Unlike other high-energy physics experiments, Muon g-2 needed more than just high-energy physicists; the collaboration is also composed of accelerator physicists, atomic physicists and nuclear physicists. 'It was very valuable to see that, when we had all these different experts come together, we could solve items that probably one group could not have done alone,' said Incagli.
While the experiment's main analysis has come to an end, there is more to be mined from the six years of Muon g-2 data. In the future, the collaboration will produce measurements of a property of the muon called the electric dipole moment as well as tests of a fundamental property of physical laws known as charge, parity, and time-reversal symmetry.
'It's a really beautiful experiment,' said Gibbons. 'The data that comes out is really exquisite. It's been a privilege to have access to this data and analyze it.'
'Of course, it's sad to end such an endeavor because it's been a large part of many of our collaborators' lives,' said Winter, who has been part of the collaboration since 2011. 'But we also want to move to the next physics that's out there, to do our best to advance the field in other areas.
'I think it will be a textbook experiment that will be a long-lasting reference for many future decades to come,' Winter added.
Fermi National Accelerator Laboratory is America's premier national laboratory for particle physics and accelerator research. Fermi Forward Discovery Group manages Fermilab for the U.S. Department of Energy Office of Science. Visit Fermilab's website at www.fnal.gov and follow us on social media.
Attachments
Muon g-2 ring
Results plot graph
CONTACT: Tracy Marc Fermilab 2242907803 TRACYM@FNAL.GOVSign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Here's What It Costs To Charge a Tesla Monthly vs. Fuel a Ford F-150
Thinking about switching from gas to electric can feel like a big leap. But when you look at the monthly cost of driving, the numbers speak for themselves, especially when you compare a Tesla to a gas-hungry Ford F-150. Read More: Check Out: We crunched the numbers using expert input, government data and real-world efficiency estimates to determine the actual cost of driving each vehicle 1,000 miles per month. Monthly Cost to Charge a Tesla at Home According to the U.S. Department of Energy (DOE), most electric vehicles (EVs) consume between 25 and 40 kilowatt-hours (kWh) per 100 miles, depending on vehicle size and efficiency. That means driving 1,000 miles per month would typically use 250 to 400 kWh of electricity. At the U.S. average residential electricity rate of 17.45 cents per kWh (as of April 2025, according to the U.S. Energy Information Administration), charging an EV at home would cost between $44 and $70 per month. For You: 'For someone who primarily charges at home, the Tesla is hands-down a winner,' said Kazimieras Urbonas, car expert and supplier excellence manager at Ovoko. 'But if you're dependent on public charging, the cost benefit drops by a huge margin.' Most public charging stations, especially fast chargers, can cost two to three times more than home electricity rates. That means if you rely heavily on public chargers, your EV charging costs could exceed $100 per month, depending on usage and location. Fuel Cost for a Ford F-150 A 2024 Ford F-150 with the 3.5L EcoBoost V6 engine gets an estimated 20 mpg combined, according to EPA ratings. Driving 1,000 miles would require about 50 gallons of gas, and at the current average price of $3.20 per gallon (as of July 2025, per AAA), that equates to approximately $160 per month in fuel costs. In other words, driving an F-150 can cost more than double what it would cost to charge a Tesla at home, and in some cases, over three times more, depending on the vehicle and charging setup. Real-World Factors That Impact Charging Costs 1. Charging Inefficiency EV efficiency ratings, like miles per kilowatt-hour, only reflect the energy used by the motor, not what you actually draw from the grid. But charging isn't perfectly efficient. According to Recurrent Auto, most Level 2 home chargers operate at 83% to 94% efficiency, meaning 6% to 17% of electricity is lost as heat or to onboard systems. So while a Tesla might use 244 kWh to drive 1,000 miles, you'll likely pull between 260 and 290 kWh from the wall, a common misconception that can lead to underestimating your electric bill. 2. Weather-Related Efficiency Loss Cold weather impacts EV range more than gas mileage. EVs can lose up to 40%, per the DOE. By comparison, gas-powered vehicles like the F-150 usually see only a 5% to 15% drop in fuel efficiency in similar temperatures. Hidden Costs on Both Sides Tesla Home charger installation: $500 to $2,000 Winter charging may be more frequent Supercharging adds cost compared to home rates Ford F-150 Fuel price volatility Routine maintenance (oil changes, filters, tune-ups): $100 to $200 per month Long-term engine wear reduces efficiency Bottom Line If you drive around 1,000 miles a month and can charge at home, a Tesla can save you a significant amount on fuel. But the real savings depend on where you charge, how you drive and how much seasonal weather affects your vehicle. Electric vehicles aren't always cheaper in every situation, but for most drivers with access to home charging, the numbers lean in Tesla's favor. More From GOBankingRates New Law Could Make Electricity Bills Skyrocket in These 4 States I'm a Self-Made Millionaire: 6 Ways I Use ChatGPT To Make a Lot of Money 5 Strategies High-Net-Worth Families Use To Build Generational Wealth 5 Types of Cars Retirees Should Stay Away From Buying This article originally appeared on Here's What It Costs To Charge a Tesla Monthly vs. Fuel a Ford F-150 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, representing 70% of AML population 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML Broad spectrum activity and excellent safety profile continue at 120 mg dose to date SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2 TUSCANY trial in newly diagnosed AML. The trial was initiated in December 2024, and the growing body of positive data includes the recently completed third cohort of 120 mg TUS in the TUS+VEN+AZA triplet therapy. Data to date from ten (10) patients across all three cohorts, 40 mg, 80 mg or 120 mg TUS dose in TUS+VEN+AZA, support the use of TUS with standard of care treatment across all AML populations, including those carrying mutations that are the most difficult to treat and those with mutated and unmutated (wildtype) FLT3 genes. The TUS+VEN+AZA triplet is being developed as a safe and well-tolerated mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. At the 120 mg TUS dose level in combination with VEN+AZA, as with the prior reported 40 mg and 80 mg TUS dose cohorts, no significant safety concerns or dose limiting toxicities (DLTs) have been observed in the TUSCANY trial, including no prolonged myelosuppression in Cycle 1 of subjects in remission, no reports of drug-related QTc prolongation or differentiation syndrome (DS), and no treatment-related deaths. Nine out of ten dosed patients remain on study across all dose cohorts and enrollment is being advanced to the 160 mg TUS dose level following the Cohort Safety Review Committee (CSRC) meeting. 'We already have data from three different TUS dose levels in the TUSCANY trial, and the data continue to strengthen at higher doses of TUS and over time. We are building a strong case for TUS+VEN+AZA as a triplet frontline therapy of choice to address a broad AML population, including subgroups with the most adverse of mutations,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. Data highlights: Comparison of CR/CRh1 Response rates2-5: VEN+AZA2 TUS+VEN+AZA All subjects 65% 90% (9/10) NPM1-mutant 67% 100% (2/2) FLT3-ITD 61% 100% (2/2) TP53-mutant 52% 100% (2/2) Comparison of MRD-negativity6 rates among All Subjects and among CR/CRh Responders3: VEN+AZA2,3 TUS+VEN+AZA Among All Subjects 23.4% 70% (7/10) Among CR/CRh Responders 40.9% 78% (7/9) Comparison of MRD-negativity rates among more difficult-to-treat Patient Subpopulations defined as Lower Benefit (TP53-mutated) and Intermediate Benefit (FLT3-ITD or RAS-mutated) relative to VEN+AZA5: VEN+AZA3,5 TUS+VEN+AZA Intermediate Benefit 27.9% 100% (3/3) Lower Benefit 14.5% 100% (2/2) TUS+VEN+AZA - CR/CRh and MRD-negativity rates among Subjects with Adverse Mutations: TP53, FLT3-ITD, RAS mutations: Achieved CR/CRh and MRD-negativity 100% (5/5) 'As illustrated in the data highlights, the addition of TUS to VEN+AZA appears to boost response rates and MRD-negativity while maintaining favorable safety and tolerability,' said Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose, 'and the 100% CR/CRh and 100% MRD-negativity rates among the five biallelic TP53-mutant, FLT3-ITD, and RAS-mutant AML cases are exciting to see, as this can correlate with longer overall survival. We have observed a trend towards achieving CRs more quickly at the higher dose levels, so we are keen to see the activity as we advance into the 160 mg TUS dose cohort.' Key messages: Addition of TUS to VEN+AZA demonstrates excellent CR/CRh rates 100% CR/CRh among all subjects treated at 80 mg and 120 mg TUS dose levels Appear to be achieving CR earlier with 120 mg TUS than with 40 mg or 80 mg Addition of TUS to VEN+AZA demonstrates excellent MRD-negativity rates MRD-negativity in 7 of 9 (78%) already achieved in patients who responded to therapy Expect patient survival to be extended with continued long-term treatment Excellent safety and well tolerated with no dose-limiting toxicities (No DLT) at completed dose levels Broad-spectrum activity including patients with adverse TP53, RAS and FLT3-ITD mutations No loss of MRD-negativity observed to date, including in one patient with over 7 months of follow up MRD-negativity and remissions continue to mature over time on therapy No relapses reported to date and no treatment related deaths The only non-responder was a patient at the initial TUS dose level (40 mg) that did not achieve TUS exposures previously associated with response Additional data are included in the new Aptose corporate presentation here. TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. The TUSCANY triplet Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on (here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences PietropaoloCorporate Communications & Investor Relations201-923-2049spietropaolo@ 1 Complete Response / Complete Response with Partial Hematological Recovery2 DiNardo et al. New England Journal of Medicine, August 2020; Volume 383(7):617-629.3 Pratz et al. Journal of Clinical Oncology, December 2021; Volume 40 (8):855-865.4 Othman et. al. Blood Neoplasia; September 2024; Volume 1 (3):1-11.5 Döhner et. al. Blood. 2024 November 21;144(21):2211-2222.6 MRD-negative indicates that the amount of Measurable Residual Disease, as assessed by central flow cytometry, is such that the proportion of leukemic cells in a bone marrow sample falls below <0.1%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data